News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
697,474 Results
Type
Article (39665)
Company Profile (247)
Press Release (657562)
Multimedia
Podcasts (47)
Webinars (12)
Section
Business (204171)
Career Advice (2008)
Deals (35416)
Drug Delivery (95)
Drug Development (81059)
Employer Resources (172)
FDA (16167)
Job Trends (14850)
News (345188)
Policy (32524)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (7)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (17)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (5)
2024 Genetown Standard (8)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (4)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (5)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Standard (2)
Academia (2556)
Accelerated approval (5)
Adcomms (20)
Allergies (82)
Alliances (49414)
ALS (87)
Alzheimer's disease (1367)
Antibody-drug conjugate (ADC) (112)
Approvals (16169)
Artificial intelligence (241)
Autoimmune disease (20)
Automation (15)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (18)
Biosimilars (104)
Biotechnology (175)
Bladder cancer (60)
Brain cancer (26)
Breast cancer (262)
Cancer (2083)
Cardiovascular disease (167)
Career advice (1675)
Career pathing (29)
CAR-T (143)
Cell therapy (403)
Cervical cancer (19)
Clinical research (65857)
Collaboration (794)
Compensation (508)
Complete response letters (19)
COVID-19 (2582)
CRISPR (37)
C-suite (223)
Cystic fibrosis (100)
Data (2051)
Decentralized trials (2)
Denatured (17)
Depression (39)
Diabetes (256)
Diagnostics (6348)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (118)
Drug pricing (96)
Drug shortages (25)
Duchenne muscular dystrophy (91)
Earnings (86353)
Editorial (36)
Employer branding (21)
Employer resources (146)
Events (111914)
Executive appointments (693)
FDA (17350)
Featured Employer (47)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (717)
Gene editing (100)
Generative AI (19)
Gene therapy (285)
GLP-1 (697)
Government (4403)
Grass and pollen (4)
Guidances (51)
Healthcare (18812)
Huntington's disease (23)
IgA nephropathy (24)
Immunology and inflammation (109)
Indications (26)
Infectious disease (2722)
Inflammatory bowel disease (133)
Inflation Reduction Act (8)
Influenza (50)
Intellectual property (91)
Interviews (311)
IPO (16496)
IRA (40)
Job creations (3628)
Job search strategy (1423)
Kidney cancer (9)
Labor market (36)
Layoffs (460)
Leadership (16)
Legal (7907)
Liver cancer (72)
Lung cancer (302)
Lymphoma (139)
Machine learning (5)
Management (58)
Manufacturing (282)
MASH (62)
Medical device (13344)
Medtech (13349)
Mergers & acquisitions (19434)
Metabolic disorders (655)
Multiple sclerosis (75)
NASH (16)
Neurodegenerative disease (84)
Neuropsychiatric disorders (24)
Neuroscience (1873)
NextGen: Class of 2025 (6513)
Non-profit (4477)
Northern California (2532)
Now hiring (38)
Obesity (353)
Opinion (203)
Ovarian cancer (73)
Pain (80)
Pancreatic cancer (80)
Parkinson's disease (146)
Partnered (21)
Patents (222)
Patient recruitment (99)
Peanut (46)
People (57222)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20515)
Phase II (29000)
Phase III (21607)
Pipeline (1115)
Policy (128)
Postmarket research (2565)
Preclinical (8680)
Press Release (64)
Prostate cancer (98)
Psychedelics (30)
Radiopharmaceuticals (244)
Rare diseases (371)
Real estate (5906)
Recruiting (65)
Regulatory (22201)
Reports (46)
Research institute (2320)
Resumes & cover letters (349)
Rett syndrome (4)
RNA editing (4)
RSV (42)
Schizophrenia (65)
Series A (124)
Series B (81)
Service/supplier (11)
Sickle cell disease (52)
Southern California (2179)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (28)
Startups (3572)
State (2)
Stomach cancer (13)
Supply chain (65)
Tariffs (24)
The Weekly (28)
United States (21993)
Vaccines (667)
Venture capitalists (38)
Weight loss (229)
Women's health (34)
Worklife (15)
Date
Today (99)
Last 7 days (481)
Last 30 days (2450)
Last 365 days (32995)
2025 (9197)
2024 (35220)
2023 (40086)
2022 (51186)
2021 (55712)
2020 (54083)
2019 (46549)
2018 (35021)
2017 (32116)
2016 (31492)
2015 (37560)
2014 (31329)
2013 (26363)
2012 (28583)
2011 (29283)
2010 (27344)
Location
Africa (718)
Alabama (52)
Alaska (7)
Arizona (229)
Arkansas (13)
Asia (37771)
Australia (6179)
California (5775)
Canada (1939)
China (489)
Colorado (253)
Connecticut (262)
Delaware (134)
Europe (81103)
Florida (860)
Georgia (202)
Idaho (57)
Illinois (513)
India (25)
Indiana (300)
Iowa (9)
Japan (149)
Kansas (102)
Kentucky (23)
Louisiana (9)
Maine (62)
Maryland (856)
Massachusetts (4330)
Michigan (215)
Minnesota (378)
Mississippi (2)
Missouri (78)
Montana (27)
Nebraska (25)
Nevada (60)
New Hampshire (62)
New Jersey (1659)
New Mexico (28)
New York (1649)
North Carolina (935)
North Dakota (7)
Northern California (2532)
Ohio (194)
Oklahoma (14)
Oregon (33)
Pennsylvania (1304)
Puerto Rico (11)
Rhode Island (30)
South America (1096)
South Carolina (20)
South Dakota (1)
Southern California (2179)
Tennessee (99)
Texas (860)
Utah (171)
Virginia (135)
Washington D.C. (59)
Washington State (530)
West Virginia (3)
Wisconsin (51)
697,474 Results for "clene nanomedicine inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Clene to Present at the Emerging Growth Conference
April 14, 2025
·
2 min read
Press Releases
Clene to Present at the Jones Healthcare and Technology Innovation Conference
April 1, 2025
·
1 min read
Press Releases
Clene to Present at the 37TH Annual Roth Conference
March 6, 2025
·
1 min read
Press Releases
Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights
March 25, 2025
·
15 min read
BioMidwest
Clene to Present at Upcoming May 2024 Conferences
Clene Inc. and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis and multiple sclerosis, announced that it will participate in the following investor conferences in May.
May 14, 2024
·
1 min read
Press Releases
Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment
March 13, 2025
·
9 min read
Press Releases
Clene Presents Evidence of Remyelination and Neuronal Repair With CNM-Au8® Treatment At the American Academy of Neurology Late-Breaking Science Session
April 9, 2025
·
7 min read
Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)
Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly-owned subsidiary Clene Nanomedicine Inc. today announced several key updates on its National Institutes of Health (NIH)-funded Accelerating Access to Critical Therapies Expanded Access Program (ACT-EAP) for CNM-Au8® compassionate use in ALS.
May 28, 2024
·
8 min read
Clene to Present at the Emerging Growth Conference
Clene Inc. today announced that management will present at the Emerging Growth Conference.
June 5, 2024
·
2 min read
Business
Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights
Clene Inc. and its wholly owned subsidiary Clene Nanomedicine, Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis and multiple sclerosis, announced its first quarter 2024 financial results and provided recent operating highlights for the CNM-Au8 clinical program for MS.
May 8, 2024
·
12 min read
1 of 69,748
Next
